Abstract:Abstract Tumor microenvironments (TME) are rich in cells that potentially inhibit T cell function, such as regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs). Many TMEs are dominated by myeloid cells, making targeting these cells an area of interest. The purpose of this study was to develop an in vitro assay system to assess the ability of novel drugs to overcome MDSC-mediated immune suppression by monitoring changes to T cell function. Arginase1 (ARG1), an enzyme that catalyzes L-arginine into L-ornithine and urea, is highly expressed in MDSCs. An ARG1 target is currently in clinical trials (INCB001158, CB-1158 from Calithera Biosciences) and was used as a target of interest in this study. MDSC generation from bone marrow cells (BM) was compared using GM-CSF and IL-6 or GM-CSF, IFNγ, and LPS. α-Difluormethylornithine (DFMO), a 2nd generation ARG1 inhibitor that irreversibly binds ARG1, which leads to increased availability of L-arginine, known to modulate T cell activity, was tested during MDSC generation. BM were harvested and characterized with a myeloid flow cytometry panel. GM-CSF, IFNγ, and LPS generated more reproducible MDSCs that express ARG1. M-MDSC-derived BM expressed 2 times more ARG1 as compared to DFMO cultured MDSC-derived BM. The cytokines and other growth factors produced by MDSC-derived BM have the potential to alter the activation state of CD8+ T cells; therefore, the effect of a suppressive TME on CD8+ T cells was monitored by co-culturing CD8+ T cells with MDSCs in vitro. MDSC-derived BM were co-cultured for 4 days with CD8+ T cells (purified from C57BL/6 splenocytes) and activated with anti-CD3/anti-CD28 beads. CD8+ T cells were characterized for proliferation using CellTraceTM violet, surface activation markers (CD69 and PD-1), and intracellular cytokines (IFNγ, TNFα, and IL-2). CD8+T cells co-cultured with DFMO-inhibited MDSC-derived BM were more proliferative, had greater surface activation, and greater intracellular cytokine of CD8+ T cells as compared to when co-cultured with MDSC-derived BM. CD8+ T cell proliferation was measured at multiple ratios of CD8+ T cells and MDSC-derived BM with a proliferation range of 88-7% when CD8+ T cells were co-cultured with MDSC-derived BM and 91-30% when co-cultured with DFMO-inhibited MDSC-derived BM. Similar trends were observed with CD69, PD-1, IFN-y, TNF-a and IL-2 expression in CD8+ T cells. Overall, the ability to monitor changes in T cell activation following MDSC has broad applications in in vitro screening of novel drug compounds that alter the TME as well as sets the experimental framework for ex vivo analysis of cells isolated from TME following treatment. Citation Format: Anita J. Zaitouna, Philip Lapinski, Amber Rowse, David Draper, Scott Wise. Inhibition of murine myeloid suppressor cells increases CD8+ T cell activation in Vitro [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2762.

Immunosuppressive Myeloid Cells Induce Nitric Oxide–Dependent DNA Damage and p53 Pathway Activation in CD8+ T Cells

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

MDSCs-derived GPR84 induces CD8+ T-cell senescence via p53 activation to suppress the antitumor response

IFN-γ producing T cells contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after cyclophosphamide treatment

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Myeloid-derived Suppressor Cells Inhibit T Cell Activation Through Nitrating LCK in Mouse Cancers.

Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6/STAT3 axis

DNA repair processes are critical mediators of p53-dependent tumor suppression

DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways

Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair

Cell Cycle Checkpoints Cooperate to Suppress DNA- and RNA-Associated Molecular Pattern Recognition and Anti-Tumor Immune Responses

Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway

Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming Through Signal Regulatory Protein Α Signaling.

Abstract 1326: Loss of p53 sensitizes tumor cells to immune checkpoint blockade therapy via upregulation of IL-33

Abstract 2762: Inhibition of murine myeloid suppressor cells increases CD8+ T cell activation in Vitro

Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

Soluble NKG2D Ligand Promotes MDSC Expansion and Skews Macrophage to the Alternatively Activated Phenotype.

Tumor suppressor p53 mediates interleukin-6 expression to enable cancer cell evasion of genotoxic stress

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade